https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2024-10-02 08:30:022024-10-02 11:27:05LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-07-27 14:11:302022-07-27 14:11:44LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-05-11 12:35:322022-05-12 09:30:42LoQus23 Therapeutics Ltd. of Cambridge, UK co-funds new research project on neurological diseases
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Amanda Davishttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngAmanda Davis2022-01-24 19:00:452022-01-25 11:27:43LoQus23 Therapeutics appoints Dr Melanie Ivarsson, OBE, as Non-Executive Director
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2021-11-23 09:00:402021-11-29 21:48:33LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2021-07-27 10:09:282021-11-18 10:23:32LoQus23 researchers awarded grant to understand if repeat instability is therapeutically relevant in Friedriech’s ataxia
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2021-02-09 10:10:202021-11-29 15:30:07LoQus23’s drug discovery approach highlighted in the Journal of Huntington’s Disease
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2020-06-12 10:10:492021-11-18 15:22:10LoQus23 presents at the HDSA convention
https://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.png00Editorhttps://loqus23.com/wp-content/uploads/2021/09/LoQus23_Logo_400px.pngEditor2019-10-15 10:11:392021-11-18 10:24:02LoQus23 secures HDSA grant to improve how we measure repeat instability in patients
LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease
LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
LoQus23 Therapeutics Ltd. of Cambridge, UK co-funds new research project on neurological diseases
LoQus23 Therapeutics appoints Dr Melanie Ivarsson, OBE, as Non-Executive Director
LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
LoQus23 researchers awarded grant to understand if repeat instability is therapeutically relevant in Friedriech’s ataxia
LoQus23’s drug discovery approach highlighted in the Journal of Huntington’s Disease
LoQus23 presents at the HDSA convention
LoQus23 secures HDSA grant to improve how we measure repeat instability in patients